Oragenics, Inc. (OGEN) Bundle
A Brief History of Oragenics, Inc. (OGEN)
Founding and Early Years
Founding and Early Years
Oragenics, Inc. was founded in 1996 and is based in Tampa, Florida. The company initially focused on the discovery and development of novel antibiotics to combat bacteria. Its focus shifted over the years to include regenerative medicine and oral health.
Public Offering and Initial Growth
In 2001, Oragenics went public, trading on the American Stock Exchange under the ticker symbol OGEN. The company raised approximately $6 million from the initial public offering. By 2003, it entered into several collaborations to further its research.
Product Development and Pipeline
Oragenics has developed a proprietary platform aimed at expanding the effectiveness of its products. As of September 2023, its major developmental programs include:
- NT-300: A biological treatment for dry mouth.
- OGEN-001: A vaccine candidate for the prevention of COVID-19.
- Oral probiotics aimed at treating oral diseases.
Financial Performance
For the fiscal year ended December 31, 2022, Oragenics reported revenue of approximately $1.5 million, primarily from product sales and grants. The company had a net loss of around $5.2 million during the same period.
The following table summarizes key financial data over recent years:
| Year | Revenue (in millions) | Net Loss (in millions) | Total Assets (in millions) |
|---|---|---|---|
| 2020 | 1.0 | 4.5 | 10.2 |
| 2021 | 1.2 | 4.8 | 11.0 |
| 2022 | 1.5 | 5.2 | 12.5 |
Strategic Collaborations
Oragenics has established strategic partnerships to enhance its research capabilities. Notable collaborations include:
- Collaboration with the University of Florida for research on oral probiotics.
- Partnerships aimed at developing novel therapeutic systems.
Current Market Position
As of October 2023, Oragenics trades on the Nasdaq under the symbol OGEN. The stock price fluctuated around $0.50 per share during the month of September 2023. The company’s market capitalization is approximately $30 million.
Challenges and Future Outlook
Oragenics faces challenges including competition in the biotech sector and regulatory hurdles. The company continues to seek funding and partnerships to advance its product pipeline and maintain operations.
A Who Owns Oragenics, Inc. (OGEN)
Current Ownership Structure
As of the latest filings and reports, here is the ownership structure of Oragenics, Inc. (OGEN):
| Shareholder Type | Percentage Owned | Number of Shares | Notes |
|---|---|---|---|
| Institutional Investors | 20.5% | 8,295,000 | Includes hedge funds, mutual funds, and pension funds. |
| Insiders | 5.6% | 2,300,000 | Includes executives and board members. |
| Retail Investors | 73.9% | 30,000,000 | General public shareholders. |
Major Institutional Investors
Key institutional investors holding significant shares of OGEN include:
| Institution | Number of Shares | Percentage of Total | Value (USD) |
|---|---|---|---|
| Vanguard Group Inc. | 3,200,000 | 8.0% | $1,600,000 |
| BlackRock Inc. | 2,300,000 | 5.6% | $1,150,000 |
| SSgA Funds Management Inc. | 1,800,000 | 4.5% | $900,000 |
Insider Holdings
Insider ownership provides insight into the confidence of management in the company's future. Here are the notable insiders and their holdings:
| Name | Position | Shares Owned | Percentage of Total |
|---|---|---|---|
| Alan M. M. S. G. Craik | CEO | 1,000,000 | 2.5% |
| David S. H. O'Keefe | CFO | 500,000 | 1.2% |
| Jane Doe | Board Member | 800,000 | 2.0% |
Stock Performance
The stock performance of Oragenics, Inc. has shown fluctuations over the past year:
| Month | Opening Price (USD) | Closing Price (USD) | Change (%) |
|---|---|---|---|
| January 2023 | 2.00 | 1.80 | -10.0% |
| February 2023 | 1.80 | 2.25 | 25.0% |
| March 2023 | 2.25 | 2.10 | -6.67% |
| April 2023 | 2.10 | 2.50 | 19.05% |
Conclusion on Ownership Insights
The ownership insights of Oragenics, Inc. indicate a majority stake held by retail investors, with significant institutional investment indicating confidence in the company’s direction. The executive and board retention of shares further emphasizes their commitment. The fluctuations in stock price reflect market reactions to the company’s performance and announcements.
Oragenics, Inc. (OGEN) Mission Statement
Corporate Overview
Oragenics, Inc. is focused on the development of innovative therapies for the prevention and treatment of infectious diseases and oral mucositis. The mission statement of the company encapsulates its commitment to improving patient health through its proprietary technology.
Mission Statement
The mission of Oragenics, Inc. is to develop and commercialize innovative therapeutics with a focus on antimicrobial and oral health solutions. It aims to provide high-quality, effective products that improve the health of patients and contribute to well-being on a global scale.
Key Aspects of Mission Statement
- Innovation: To pioneer novel therapeutic solutions that address unmet medical needs.
- Quality: To ensure high standards in product development and manufacturing processes.
- Global Reach: To extend the benefits of its products to patients worldwide.
- Patient-Centric Approach: To prioritize patient health and safety in every initiative undertaken by the company.
Financial Overview
As of the latest financial report from Q2 2023, Oragenics, Inc. reported the following financial data:
| Metric | Q2 2023 Amount |
|---|---|
| Total Revenue | $0.62 million |
| Net Loss | ($2.41 million) |
| Cash and Cash Equivalents | $5.12 million |
| R&D Expenses | $1.34 million |
| Operating Expenses | $2.08 million |
| Market Capitalization | $43 million |
Research and Development Focus
Oragenics is engaged in extensive R&D efforts, particularly aimed at:
- Development of OGEN-001 - a potential treatment for oral mucositis.
- Creation of antimicrobial peptides targeting antibiotic-resistant bacteria.
- Advancements in probiotic formulations for enhanced oral health.
Strategic Partnerships
The company actively seeks collaborations to enhance its research capabilities and market reach, including:
- Collaboration with leading academic institutions.
- Partnerships with pharmaceutical companies for co-development projects.
- Engagement with regulatory agencies for clinical path guidance.
Future Outlook and Goals
Oragenics aims to achieve several key milestones by 2025:
- Complete Phase II clinical trials for OGEN-001.
- Launch of at least one product in the antimicrobial space.
- Expand partnerships to enhance market access globally.
How Oragenics, Inc. (OGEN) Works
Company Overview
Oragenics, Inc. is a biotechnology company focused on the development of novel antibiotics and treatments for diseases, particularly those caused by drug-resistant bacteria. As of September 30, 2023, Oragenics reported total assets of approximately $4.5 million.
Financial Performance
For the third quarter of 2023, Oragenics reported a net revenue of $0.5 million, with total operating expenses of around $2.1 million. This resulted in a net loss of approximately $1.6 million for the quarter.
| Quarter | Net Revenue | Operating Expenses | Net Loss |
|---|---|---|---|
| Q3 2023 | $0.5 million | $2.1 million | $(1.6 million) |
| Q2 2023 | $0.6 million | $1.9 million | $(1.3 million) |
| Q1 2023 | $0.4 million | $2.0 million | $(1.6 million) |
Research and Development Pipeline
Oragenics focuses on advancing its proprietary antibiotic candidate, which targets the treatment of serious infections. As of October 2023, the company has completed Phase 1 clinical trials with positive safety results.
Market Position and Strategy
Oragenics operates in the competitive landscape of antibiotic development with a strategic focus on addressing unmet medical needs. The global antibiotic market size was valued at approximately $45 billion in 2022 and is expected to grow at a CAGR of 3.5% from 2023 to 2030.
Funding and Investment
As of the end of Q3 2023, Oragenics has a cash balance of approximately $3 million, bolstered by a recent financing round that raised $2 million in July 2023.
| Funding Round | Date | Amount Raised |
|---|---|---|
| Private Placement | July 2023 | $2 million |
| Public Offering | February 2023 | $5 million |
| Grant Funding | January 2023 | $1 million |
Collaborations and Partnerships
Oragenics has established strategic collaborations with academic institutions and other biotech firms. Notably, in 2023, the company partnered with University Hospital's research team for the development of antibiotic resistance solutions.
Management and Leadership
Oragenics is led by a team of experienced professionals in the biotechnology sector. The CEO, Dr. Alan Joslyn, has over 20 years of experience in the pharmaceutical industry. As of October 2023, the Board of Directors includes specialists with backgrounds in drug development and commercialization.
Stock Performance
Oragenics, Inc. trades on the NYSE American under the symbol OGEN. As of October 27, 2023, the stock price is approximately $0.45, with a market capitalization of $10 million. The stock has demonstrated volatility, with a 52-week range of $0.30 to $1.00.
| Stock Information | Current Price | Market Cap | 52-Week Range |
|---|---|---|---|
| OGEN | $0.45 | $10 million | $0.30 - $1.00 |
How Oragenics, Inc. (OGEN) Makes Money
Revenue Streams
Oragenics, Inc. generates revenue through several channels, primarily focusing on pharmaceutical developments and collaborations with larger entities.
Product Development and Licensing Agreements
Oragenics focuses on the development of new antibiotic therapies. In recent years, the company has established partnerships that are integral to its monetary inflow.
| Year | Licensing Revenue ($ millions) | Collaborative Revenue ($ millions) |
|---|---|---|
| 2021 | 0.5 | 2.3 |
| 2022 | 1.0 | 3.1 |
| 2023 | 0.7 | 2.8 |
Grants and Funding
Oragenics secures significant funding from government and private sectors to support its research initiatives.
| Funding Source | Amount ($ millions) | Year |
|---|---|---|
| National Institutes of Health (NIH) | 3.5 | 2022 |
| Department of Defense (DoD) | 2.0 | 2023 |
| Private Investors | 5.0 | 2021 |
Sales of Products
The company has developed products intended for the treatment of bacterial infections. However, revenue from product sales has varied.
| Year | Product Sales ($ millions) | Growth Rate (%) |
|---|---|---|
| 2021 | 4.0 | - |
| 2022 | 3.5 | -12.5 |
| 2023 | 5.2 | 48.6 |
Investment Income
The company also makes money through investment income from its cash reserves and short-term investments.
| Year | Investment Income ($ millions) | Percentage of Total Revenue (%) |
|---|---|---|
| 2021 | 0.2 | 2.0 |
| 2022 | 0.4 | 4.0 |
| 2023 | 0.3 | 3.5 |
Strategic Partnerships
Oragenics engages in strategic partnerships, which provide access to wider markets and shared research initiatives, adding to their revenue model.
- Partnership with Tetra Bio-Pharma: Focused on developing therapeutic drugs.
- Collaboration with large pharmaceutical firms: Aims to enhance R&D capabilities and distribution networks.
- Engagement with academic institutions: Aligns on groundbreaking research and clinical trials.
Future Projections
Based on current trends, Oragenics anticipates potential revenue increases from its pipeline products, along with improved collaboration agreements.
| Year | Projected Revenue ($ millions) | Key Products |
|---|---|---|
| 2024 | 10.0 | Antibiotic "OGN-103" |
| 2025 | 15.0 | Therapeutic "OGN-201" |
| 2026 | 20.0 | New Vaccine Initiative |
Oragenics, Inc. (OGEN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support